메뉴 건너뛰기




Volumn 38, Issue 9, 2013, Pages 1002-1024

Review article: Dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; ALPHA INTERFERON; ALPHA4BETA7 INTEGRIN; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CALCINEURIN INHIBITOR; CD3 ANTIGEN; CD4 ANTIGEN; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; INFLIXIMAB; INTEGRIN; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 23; JANUS KINASE 1; JANUS KINASE 2; METHOTREXATE; NATALIZUMAB; PLACEBO; TACROLIMUS; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VEDOLIZUMAB;

EID: 84885116915     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12491     Document Type: Article
Times cited : (69)

References (230)
  • 2
    • 33748120753 scopus 로고    scopus 로고
    • Economic burden of inflammatory bowel disease: A UK perspective
    • DOI 10.1586/14737167.6.4.471
    • Luces C, Bodger K,. Economic burden of inflammatory bowel disease: a UK perspective. Expert Rev Pharmacoecon Outcomes Res 2006; 6: 471-82. (Pubitemid 44304755)
    • (2006) Expert Review of Pharmacoeconomics and Outcomes Research , vol.6 , Issue.4 , pp. 471-482
    • Luces, C.1    Bodger, K.2
  • 5
    • 84989078407 scopus 로고
    • The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine
    • Elion GB,. The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine. Ann N Y Acad Sci 1993; 685: 400-7.
    • (1993) Ann N y Acad Sci , vol.685 , pp. 400-407
    • Elion, G.B.1
  • 6
    • 79959454066 scopus 로고    scopus 로고
    • A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: The TARGET study
    • Newman WG, Payne K, Tricker K, et al,. A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics 2011; 12: 815-26.
    • (2011) Pharmacogenomics , vol.12 , pp. 815-826
    • Newman, W.G.1    Payne, K.2    Tricker, K.3
  • 7
    • 0018822866 scopus 로고
    • Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity
    • Weinshilboum RM, Sladek SL,. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-62. (Pubitemid 10061685)
    • (1980) American Journal of Human Genetics , vol.32 , Issue.5 , pp. 651-662
    • Weinshilboum, R.M.1    Sladek, S.L.2
  • 8
    • 37549016742 scopus 로고    scopus 로고
    • Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease
    • Lees CW, Maan AK, Hansoti B, et al,. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 27: 220-7.
    • (2008) Aliment Pharmacol Ther , vol.27 , pp. 220-227
    • Lees, C.W.1    Maan, A.K.2    Hansoti, B.3
  • 9
    • 51349085433 scopus 로고    scopus 로고
    • Sweet syndrome as a manifestation of azathioprine hypersensitivity
    • El-Azhary RA, Brunner KL, Gibson LE,. Sweet syndrome as a manifestation of azathioprine hypersensitivity. Mayo Clin Proc 2008; 83: 1026-30.
    • (2008) Mayo Clin Proc , vol.83 , pp. 1026-1030
    • El-Azhary, R.A.1    Brunner, K.L.2    Gibson, L.E.3
  • 10
    • 34250716940 scopus 로고    scopus 로고
    • Erythema nodosum-like eruption as a manifestation of azathioprine hypersensitivity in patients with inflammatory bowel disease
    • DOI 10.1001/archderm.143.6.744
    • de Fonclare AL, Khosrotehrani K, Aractingi S, et al,. Erythema nodosum-like eruption as a manifestation of azathioprine hypersensitivity in patients with inflammatory bowel disease. Arch Dermatol 2007; 143: 744-8. (Pubitemid 46955733)
    • (2007) Archives of Dermatology , vol.143 , Issue.6 , pp. 744-748
    • De Fonclare, A.-L.1    Khosrotehrani, K.2    Aractingi, S.3    Duriez, P.4    Cosnes, J.5    Beaugerie, L.6
  • 11
    • 33845771801 scopus 로고    scopus 로고
    • Acute generalized exanthematous pustulosis associated with azathioprine hypersensitivity
    • DOI 10.1111/j.1365-2230.2006.02257.x
    • Elston GE, Johnston GA, Mortimer NJ, et al,. Acute generalized exanthematous pustulosis associated with azathioprine hypersensitivity. Clin Exp Dermatol 2007; 32: 52-3. (Pubitemid 46006367)
    • (2007) Clinical and Experimental Dermatology , vol.32 , Issue.1 , pp. 52-53
    • Elston, G.E.1    Johnston, G.A.2    Mortimer, N.J.3    Harman, K.E.4
  • 12
    • 0037098931 scopus 로고    scopus 로고
    • Erythema gyratum repens: Arzneimittelreaktion nach azathioprin bei einer patientin mit autoimmunhepatitis typ I
    • DOI 10.1007/s00063-002-1175-3
    • Gunther R, Nasser S, Hinrichsen H, et al,. Erythema gyratum repens: drug reaction following azathioprine administration in a patient with type I autoimmune hepatitis. Med Klin (Munich) 2002; 97: 414-7. (Pubitemid 34803352)
    • (2002) Medizinische Klinik , vol.97 , Issue.7 , pp. 414-417
    • Gunther, R.1    Nasser, S.2    Hinrichsen, H.3    Folsch, U.R.4
  • 15
    • 33845310903 scopus 로고    scopus 로고
    • Incidence and Risk Factors for Herpes Zoster Among Patients With Inflammatory Bowel Disease
    • DOI 10.1016/j.cgh.2006.09.019, PII S1542356506009475
    • Gupta G, Lautenbach E, Lewis JD,. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 1483-90. (Pubitemid 44880029)
    • (2006) Clinical Gastroenterology and Hepatology , vol.4 , Issue.12 , pp. 1483-1490
    • Gupta, G.1    Lautenbach, E.2    Lewis, J.D.3
  • 17
    • 67349134712 scopus 로고    scopus 로고
    • European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
    • Rahier JF, Ben-Horin S, Chowers Y, et al,. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3: 47-91.
    • (2009) J Crohns Colitis , vol.3 , pp. 47-91
    • Rahier, J.F.1    Ben-Horin, S.2    Chowers, Y.3
  • 18
    • 84885140694 scopus 로고    scopus 로고
    • FDA. US Food and Drug administration Accessed November 11, 2013
    • FDA. US Food and Drug administration. FDA product information for IMURAN. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 016324s034s035lbl.pdf. Accessed November 11, 2013.
    • FDA Product Information for IMURAN
  • 19
    • 55149118807 scopus 로고    scopus 로고
    • Risk of nonmelanoma skin cancer with azathioprine use
    • Maddox JS, Soltani K,. Risk of nonmelanoma skin cancer with azathioprine use. Inflamm Bowel Dis 2008; 14: 1425-31.
    • (2008) Inflamm Bowel Dis , vol.14 , pp. 1425-1431
    • Maddox, J.S.1    Soltani, K.2
  • 21
    • 1442311442 scopus 로고    scopus 로고
    • Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate
    • DOI 10.1097/01.TP.0000108491.62935.DF
    • Bordea C, Wojnarowska F, Millard PR, et al,. Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation 2004; 77: 574-9. (Pubitemid 38282815)
    • (2004) Transplantation , vol.77 , Issue.4 , pp. 574-579
    • Bordea, C.1    Wojnarowska, F.2    Millard, P.R.3    Doll, H.4    Welsh, K.5    Morris, P.J.6
  • 22
    • 0029070647 scopus 로고
    • Malignant disease in patients with long-term renal transplants
    • Gaya SB, Rees AJ, Lechler RI, et al,. Malignant disease in patients with long-term renal transplants. Transplantation 1995; 59: 1705-9.
    • (1995) Transplantation , vol.59 , pp. 1705-1709
    • Gaya, S.B.1    Rees, A.J.2    Lechler, R.I.3
  • 24
    • 0026669515 scopus 로고
    • Malignancy following renal transplantation
    • Sheil AG, Disney AP, Mathew TG, et al,. Malignancy following renal transplantation. Transplant Proc 1992; 24: 1946-7.
    • (1992) Transplant Proc , vol.24 , pp. 1946-1947
    • Sheil, A.G.1    Disney, A.P.2    Mathew, T.G.3
  • 25
    • 0015840007 scopus 로고
    • Risk of cancer in renal-transplant recipients
    • Hoover R, Fraumeni JF Jr,. Risk of cancer in renal-transplant recipients. Lancet 1973; 2: 55-7.
    • (1973) Lancet , vol.2 , pp. 55-57
    • Hoover, R.1    Fraumeni, Jr.J.F.2
  • 26
  • 27
    • 33746866362 scopus 로고    scopus 로고
    • Azathioprine in dermatology: The past, the present, and the future
    • DOI 10.1016/j.jaad.2005.07.059, PII S0190962205023844
    • Patel AA, Swerlick RA, McCall CO,. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol 2006; 55: 369-89. (Pubitemid 44189574)
    • (2006) Journal of the American Academy of Dermatology , vol.55 , Issue.3 , pp. 369-389
    • Patel, A.A.1    Swerlick, R.A.2    McCall, C.O.3
  • 28
    • 0027731258 scopus 로고
    • Incidence and treatment of neoplasia after transplantation
    • Penn I,. Incidence and treatment of neoplasia after transplantation. J Heart Lung Transplant 1993; 12: S328-36. (Pubitemid 24018966)
    • (1993) Journal of Heart and Lung Transplantation , vol.12 , Issue.6
    • Penn, I.1
  • 29
    • 0032811701 scopus 로고    scopus 로고
    • Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases
    • Asten P, Barrett J, Symmons D,. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999; 26: 1705-14. (Pubitemid 29367309)
    • (1999) Journal of Rheumatology , vol.26 , Issue.8 , pp. 1705-1714
    • Asten, P.1    Barrett, J.2    Symmons, D.3
  • 30
    • 0022004061 scopus 로고
    • Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment
    • DOI 10.1016/0002-9343(85)90245-1
    • Kinlen LJ,. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985; 78: 44-9. (Pubitemid 15167365)
    • (1985) American Journal of Medicine , vol.78 , Issue.1 A , pp. 44-49
    • Kinlen, L.J.1
  • 31
    • 0018599063 scopus 로고
    • Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs
    • Kinlen LJ, Sheil AG, Peto J, et al,. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 1979; 2: 1461-6. (Pubitemid 10162309)
    • (1979) British Medical Journal , vol.2 , Issue.6203 , pp. 1461-1466
    • Kinlen, L.J.1    Sheil, A.G.R.2    Peto, J.3    Doll, R.4
  • 32
    • 0031912356 scopus 로고    scopus 로고
    • Lymphocyte subsets and Langerhans cells in sun-protected and sun- exposed skin of immunosuppressed renal allograft recipients
    • DOI 10.1016/S0190-9622(98)70536-5
    • Galvao MM, Sotto MN, Kihara SM, et al,. Lymphocyte subsets and Langerhans cells in sun-protected and sun-exposed skin of immunosuppressed renal allograft recipients. J Am Acad Dermatol 1998; 38: 38-44. (Pubitemid 28100463)
    • (1998) Journal of the American Academy of Dermatology , vol.38 , Issue.1 , pp. 38-44
    • Galvao, M.M.1    Sotto, M.N.2    Kihara, S.M.3    Rivitti, E.A.4    Sabbaga, E.5
  • 34
    • 79960286604 scopus 로고    scopus 로고
    • Nonmelanoma skin cancers in four IBD patients on treatment with immunosuppressive agents
    • Angelucci E, Cesarini M, Vernia P,. Nonmelanoma skin cancers in four IBD patients on treatment with immunosuppressive agents. Inflamm Bowel Dis 2011; 17: 1827-9.
    • (2011) Inflamm Bowel Dis , vol.17 , pp. 1827-1829
    • Angelucci, E.1    Cesarini, M.2    Vernia, P.3
  • 35
    • 0035131123 scopus 로고    scopus 로고
    • Inflammatory bowel disease, azathioprine and skin cancer: Case report and literature review
    • DOI 10.1097/00042737-200102000-00017
    • Austin AS, Spiller RC,. Inflammatory bowel disease, azathioprine and skin cancer: case report and literature review. Eur J Gastroenterol Hepatol 2001; 13: 193-4. (Pubitemid 32158215)
    • (2001) European Journal of Gastroenterology and Hepatology , vol.13 , Issue.2 , pp. 193-194
    • Austin, A.S.1    Spiller, R.C.2
  • 36
    • 77956656196 scopus 로고    scopus 로고
    • Multiple cutaneous malignancies arising in a patient with Crohn disease treated with concomitant azathioprine and antitumour necrosis factor-alpha
    • Fogo AJ, Hunt JB, Clement M,. Multiple cutaneous malignancies arising in a patient with Crohn disease treated with concomitant azathioprine and antitumour necrosis factor-alpha. Clin Exp Dermatol 2010; 35: 793-5.
    • (2010) Clin Exp Dermatol , vol.35 , pp. 793-795
    • Fogo, A.J.1    Hunt, J.B.2    Clement, M.3
  • 37
    • 77349117814 scopus 로고    scopus 로고
    • Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease
    • Long MD, Herfarth HH, Pipkin CA, et al,. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010; 8: 268-74.
    • (2010) Clin Gastroenterol Hepatol , vol.8 , pp. 268-274
    • Long, M.D.1    Herfarth, H.H.2    Pipkin, C.A.3
  • 38
    • 79952457521 scopus 로고    scopus 로고
    • Multiple and fulminant cutaneous squamous cell carcinomas in a Crohn's disease patient treated with immunosuppressants and adalimumab
    • Nancey S, Boschetti G, Cotte E, et al,. Multiple and fulminant cutaneous squamous cell carcinomas in a Crohn's disease patient treated with immunosuppressants and adalimumab. Inflamm Bowel Dis 2011; 17: 1060-1.
    • (2011) Inflamm Bowel Dis , vol.17 , pp. 1060-1061
    • Nancey, S.1    Boschetti, G.2    Cotte, E.3
  • 39
    • 79955025395 scopus 로고    scopus 로고
    • Risk of nonmelanoma skin cancer in patients with inflammatory bowel disease who use thiopurines is not increased
    • e441; author reply 450-441
    • van Schaik FD, van Oijen MG, Smeets HM, et al,. Risk of nonmelanoma skin cancer in patients with inflammatory bowel disease who use thiopurines is not increased. Clin Gastroenterol Hepatol 2011; 9: 449-50. e441; author reply 450-441
    • (2011) Clin Gastroenterol Hepatol , vol.9 , pp. 449-450
    • Van Schaik, F.D.1    Van Oijen, M.G.2    Smeets, H.M.3
  • 40
    • 0022410723 scopus 로고
    • Extraintestinal cancers in inflammatory bowel disease
    • DOI 10.1002/1097-0142(19851215)56:12 <2914::AID-CNCR2820561232>3.0. CO;2-J
    • Greenstein AJ, Gennuso R, Sachar DB, et al,. Extraintestinal cancers in inflammatory bowel disease. Cancer 1985; 56: 2914-21. (Pubitemid 16216306)
    • (1985) Cancer , vol.56 , Issue.12 , pp. 2914-2921
    • Greenstein, A.J.1    Gennuso, R.2    Sachar, D.B.3
  • 41
    • 0028815367 scopus 로고
    • Cancer in patients with ulcerative colitis
    • Mellemkjaer L, Olsen JH, Frisch M, et al,. Cancer in patients with ulcerative colitis. Int J Cancer 1995; 60: 330-3.
    • (1995) Int J Cancer , vol.60 , pp. 330-333
    • Mellemkjaer, L.1    Olsen, J.H.2    Frisch, M.3
  • 42
    • 0026100447 scopus 로고
    • Extracolonic malignancies in inflammatory bowel disease
    • Ekbom A, Helmick C, Zack M, et al,. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991; 67: 2015-9.
    • (1991) Cancer , vol.67 , pp. 2015-2019
    • Ekbom, A.1    Helmick, C.2    Zack, M.3
  • 43
    • 0036024192 scopus 로고    scopus 로고
    • Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine
    • Fraser AG, Orchard TR, Robinson EM, et al,. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002; 16: 1225-32.
    • (2002) Aliment Pharmacol Ther , vol.16 , pp. 1225-1232
    • Fraser, A.G.1    Orchard, T.R.2    Robinson, E.M.3
  • 44
    • 84856193112 scopus 로고    scopus 로고
    • Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: A cohort study
    • Setshedi M, Epstein D, Winter TA, et al,. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol 2012; 27: 385-9.
    • (2012) J Gastroenterol Hepatol , vol.27 , pp. 385-389
    • Setshedi, M.1    Epstein, D.2    Winter, T.A.3
  • 45
    • 80054862378 scopus 로고    scopus 로고
    • Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease
    • e1625
    • Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al,. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141: 1621-8, e1625.
    • (2011) Gastroenterology , vol.141 , pp. 1621-1628
    • Peyrin-Biroulet, L.1    Khosrotehrani, K.2    Carrat, F.3
  • 46
    • 68949122579 scopus 로고    scopus 로고
    • Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine
    • Guenova E, Lichte V, Hoetzenecker W, et al,. Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine. Melanoma Res 2009; 19: 271-3.
    • (2009) Melanoma Res , vol.19 , pp. 271-273
    • Guenova, E.1    Lichte, V.2    Hoetzenecker, W.3
  • 47
    • 79951771271 scopus 로고    scopus 로고
    • Regression of advanced melanoma upon withdrawal of immunosuppression: Case series and literature review
    • Dillon P, Thomas N, Sharpless N, et al,. Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review. Med Oncol 2010; 27: 1127-32.
    • (2010) Med Oncol , vol.27 , pp. 1127-1132
    • Dillon, P.1    Thomas, N.2    Sharpless, N.3
  • 48
    • 77954316696 scopus 로고    scopus 로고
    • Primary cutaneous lymphoma associated with Epstein-Barr virus and azathioprine therapy
    • McAleer MA, D'Arcy CA, Mulligan NJ, et al,. Primary cutaneous lymphoma associated with Epstein-Barr virus and azathioprine therapy. Clin Exp Dermatol 2010; 35: 674-6.
    • (2010) Clin Exp Dermatol , vol.35 , pp. 674-676
    • McAleer, M.A.1    D'Arcy, C.A.2    Mulligan, N.J.3
  • 49
    • 22644446331 scopus 로고    scopus 로고
    • Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
    • DOI 10.1136/gut.2004.049460
    • Kandiel A, Fraser AG, Korelitz BI, et al,. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54: 1121-5. (Pubitemid 41025906)
    • (2005) Gut , vol.54 , Issue.8 , pp. 1121-1125
    • Kandiel, A.1    Fraser, A.G.2    Korelitz, B.I.3    Brensinger, C.4    Lewis, J.D.5
  • 50
    • 67949112671 scopus 로고    scopus 로고
    • Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: A meta-analysis
    • Siegel CA, Marden SM, Persing SM, et al,. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 874-81.
    • (2009) Clin Gastroenterol Hepatol , vol.7 , pp. 874-881
    • Siegel, C.A.1    Marden, S.M.2    Persing, S.M.3
  • 51
    • 33846448180 scopus 로고    scopus 로고
    • Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease
    • DOI 10.1345/aph.1H219
    • Masunaga Y, Ohno K, Ogawa R, et al,. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother 2007; 41: 21-8. (Pubitemid 46145952)
    • (2007) Annals of Pharmacotherapy , vol.41 , Issue.1 , pp. 21-28
    • Masunaga, Y.1    Ohno, K.2    Ogawa, R.3    Hashiguchi, M.4    Echizen, H.5    Ogata, H.6
  • 52
    • 82955195113 scopus 로고    scopus 로고
    • Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease
    • Herrinton LJ, Liu L, Weng X, et al,. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 2011; 106: 2146-53.
    • (2011) Am J Gastroenterol , vol.106 , pp. 2146-2153
    • Herrinton, L.J.1    Liu, L.2    Weng, X.3
  • 53
    • 80051480954 scopus 로고    scopus 로고
    • Risk of malignant lymphoma in patients with inflammatory bowel diseases: A Dutch nationwide study
    • Vos AC, Bakkal N, Minnee RC, et al,. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis 2011; 17: 1837-45.
    • (2011) Inflamm Bowel Dis , vol.17 , pp. 1837-1845
    • Vos, A.C.1    Bakkal, N.2    Minnee, R.C.3
  • 54
    • 70449100743 scopus 로고    scopus 로고
    • Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study
    • Beaugerie L, Brousse N, Bouvier AM, et al,. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25.
    • (2009) Lancet , vol.374 , pp. 1617-1625
    • Beaugerie, L.1    Brousse, N.2    Bouvier, A.M.3
  • 55
    • 80053484439 scopus 로고    scopus 로고
    • British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011
    • Meggitt SJ, Anstey AV, Mohd Mustapa MF, et al,. British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011. Br J Dermatol 2011; 165: 711-34.
    • (2011) Br J Dermatol , vol.165 , pp. 711-734
    • Meggitt, S.J.1    Anstey, A.V.2    Mohd Mustapa, M.F.3
  • 57
    • 11444251484 scopus 로고    scopus 로고
    • The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules
    • DOI 10.1016/j.clim.2004.09.001, PII S1521661604002748
    • Johnston A, Gudjonsson JE, Sigmundsdottir H, et al,. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005; 114: 154-63. (Pubitemid 40082381)
    • (2005) Clinical Immunology , vol.114 , Issue.2 , pp. 154-163
    • Johnston, A.1    Gudjonsson, J.E.2    Sigmundsdottir, H.3    Runar Ludviksson, B.4    Valdimarsson, H.5
  • 59
    • 33845666783 scopus 로고    scopus 로고
    • Three cases of toxic skin eruptions associated with methotrexate and a compilation of methotrexate-induced skin eruptions
    • Scheinfeld N,. Three cases of toxic skin eruptions associated with methotrexate and a compilation of methotrexate-induced skin eruptions. Dermatol Online J 2006; 12: 15.
    • (2006) Dermatol Online J , vol.12 , pp. 15
    • Scheinfeld, N.1
  • 61
    • 0023221735 scopus 로고
    • Methotrexate-induced epidermal necrosis
    • DOI 10.1111/j.1365-2133.1987.tb04907.x
    • Harrison PV,. Methotrexate-induced epidermal necrosis. Br J Dermatol 1987; 116: 867-9. (Pubitemid 17075408)
    • (1987) British Journal of Dermatology , vol.116 , Issue.6 , pp. 867-869
    • Harrison, P.V.1
  • 62
    • 0033764093 scopus 로고    scopus 로고
    • Stevens-Johnson syndrome-like exanthema secondary to methotrexate histologically simulating acute graft-versus-host disease
    • Hani N, Casper C, Groth W, et al,. Stevens-Johnson syndrome-like exanthema secondary to methotrexate histologically simulating acute graft-versus-host disease. Eur J Dermatol 2000; 10: 548-50.
    • (2000) Eur J Dermatol , vol.10 , pp. 548-550
    • Hani, N.1    Casper, C.2    Groth, W.3
  • 63
    • 0027309532 scopus 로고
    • Stevens-Johnson syndrome associated with methotrexate treatment for non-Hodgkin's lymphoma
    • Cuthbert RJ, Craig JI, Ludlam CA,. Stevens-Johnson syndrome associated with methotrexate treatment for non-Hodgkin's lymphoma. Ulster Med J 1993; 62: 95-7. (Pubitemid 23177061)
    • (1993) Ulster Medical Journal , vol.62 , Issue.1 , pp. 95-97
    • Cuthbert, R.J.G.1    Craig, J.I.O.2    Ludlam, C.A.3
  • 64
    • 77949911624 scopus 로고    scopus 로고
    • Erythema gyratum repens-like eruption occurring in resolving psoriasis during methotrexate therapy
    • Singal A, Sonthalia S, Pandhi D,. Erythema gyratum repens-like eruption occurring in resolving psoriasis during methotrexate therapy. Int J Dermatol 2010; 49: 306-7.
    • (2010) Int J Dermatol , vol.49 , pp. 306-307
    • Singal, A.1    Sonthalia, S.2    Pandhi, D.3
  • 66
    • 35148830443 scopus 로고    scopus 로고
    • Reversal of multifocal cutaneous lymphoproliferative disease associated with Epstein-Barr virus after withdrawal of methotrexate therapy for rheumatoid arthritis
    • DOI 10.1016/j.jaad.2005.09.015, PII S0190962205030069
    • Maruani A, Wierzbicka E, Machet MC, et al,. Reversal of multifocal cutaneous lymphoproliferative disease associated with Epstein-Barr virus after withdrawal of methotrexate therapy for rheumatoid arthritis. J Am Acad Dermatol 2007; 57: S69-71. (Pubitemid 47552632)
    • (2007) Journal of the American Academy of Dermatology , vol.57 , Issue.5 SUPPL.
    • Maruani, A.1    Wierzbicka, E.2    Machet, M.-C.3    Abdallah-Lotf, M.4    De Muret, A.5    Machet, L.6
  • 67
    • 0029953901 scopus 로고    scopus 로고
    • Reversible cutaneous lymphoma occurring during methotrexate therapy
    • Viraben R, Brousse P, Lamant L,. Reversible cutaneous lymphoma occurring during methotrexate therapy. Br J Dermatol 1996; 135: 116-8. (Pubitemid 26225129)
    • (1996) British Journal of Dermatology , vol.135 , Issue.1 , pp. 116-118
    • Viraben, R.1    Brousse, P.2    Lamant, L.3
  • 68
    • 79951886446 scopus 로고    scopus 로고
    • Primary cutaneous Epstein-Barr virus-associated B-cell lymphoma arising at the site of subcutaneous injections of methotrexate
    • Giard C, Avenel-Audran M, Croue A, et al,. Primary cutaneous Epstein-Barr virus-associated B-cell lymphoma arising at the site of subcutaneous injections of methotrexate. J Clin Oncol 2010; 28: e717-8.
    • (2010) J Clin Oncol , vol.28
    • Giard, C.1    Avenel-Audran, M.2    Croue, A.3
  • 70
    • 75149161836 scopus 로고    scopus 로고
    • The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
    • Dignass A, Van Assche G, Lindsay JO, et al,. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28-62.
    • (2010) J Crohns Colitis , vol.4 , pp. 28-62
    • Dignass, A.1    Van Assche, G.2    Lindsay, J.O.3
  • 72
    • 18944406360 scopus 로고    scopus 로고
    • Cyclosporine A for induction of remission in severe ulcerative colitis
    • Shibolet O, Regushevskaya E, Brezis M, et al,. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev. 2005; (1): CD004277.
    • (2005) Cochrane Database Syst Rev , Issue.1
    • Shibolet, O.1    Regushevskaya, E.2    Brezis, M.3
  • 74
    • 84885139150 scopus 로고    scopus 로고
    • FDA
    • FDA. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2009/050715s027,050716s028lbl.pdf.
  • 75
    • 0025326783 scopus 로고
    • Side-effect profile of cyclosporin A in patients treated for psoriasis
    • DOI 10.1111/j.1365-2133.1990.tb02882.x
    • Krupp P, Monka C,. Side-effect profile of cyclosporin A in patients treated for psoriasis. Br J Dermatol 1990; 122 (Suppl. 36): 47-56. (Pubitemid 20176063)
    • (1990) British Journal of Dermatology , vol.122 , Issue.SUPPL. 36 , pp. 47-56
    • Krupp, P.1    Monka, C.2
  • 76
    • 77952628621 scopus 로고    scopus 로고
    • Posttransplant cutaneous T-cell lymphoma: Case reports and review of the association of calcineurin inhibitor use with posttransplant lymphoproliferative disease risk
    • Pomerantz RG, Campbell LS, Jukic DM, et al,. Posttransplant cutaneous T-cell lymphoma: case reports and review of the association of calcineurin inhibitor use with posttransplant lymphoproliferative disease risk. Arch Dermatol 2010; 146: 513-6.
    • (2010) Arch Dermatol , vol.146 , pp. 513-516
    • Pomerantz, R.G.1    Campbell, L.S.2    Jukic, D.M.3
  • 77
    • 33645012428 scopus 로고    scopus 로고
    • Primary cutaneous T-cell lymphoma occurring after organ transplantation
    • Ravat FE, Spittle MF, Russell-Jones R,. Primary cutaneous T-cell lymphoma occurring after organ transplantation. J Am Acad Dermatol 2006; 54: 668-75.
    • (2006) J Am Acad Dermatol , vol.54 , pp. 668-675
    • Ravat, F.E.1    Spittle, M.F.2    Russell-Jones, R.3
  • 78
    • 34250218557 scopus 로고    scopus 로고
    • Ocular involvement by T-cell post-transplant lymphoproliferative disorder of cutaneous origin [6]
    • DOI 10.1080/00313020701329831, PII 778818363
    • Velankar MM, Kini AR,. Ocular involvement by T-cell post-transplant lymphoproliferative disorder of cutaneous origin. Pathology 2007; 39: 369-71. (Pubitemid 46897589)
    • (2007) Pathology , vol.39 , Issue.3 , pp. 369-371
    • Velankar, M.M.1    Kini, A.R.2
  • 79
    • 46049098155 scopus 로고    scopus 로고
    • Mycosis fungoides in a lung transplant recipient with advanced ciclosporin nephropathy: Management with mechlorethamine and subsequent renal transplantation
    • DOI 10.1159/000128283
    • Laffitte E, Venetz JP, Aubert JD, et al,. Mycosis fungoides in a lung transplant recipient with advanced ciclosporin nephropathy: management with mechlorethamine and subsequent renal transplantation. Dermatology 2008; 217: 87-8. (Pubitemid 351896579)
    • (2008) Dermatology , vol.217 , Issue.1 , pp. 87-88
    • Laffitte, E.1    Venetz, J.-P.2    Aubert, J.-D.3    Duchosal, M.A.4    Panizzon, R.G.5    Pascual, M.6
  • 81
    • 0036909110 scopus 로고    scopus 로고
    • Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis
    • DOI 10.1046/j.1365-2036.2002.01385.x
    • Domenech E, Garcia-Planella E, Bernal I, et al,. Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 2061-5. (Pubitemid 36009169)
    • (2002) Alimentary Pharmacology and Therapeutics , vol.16 , Issue.12 , pp. 2061-2065
    • Domenech, E.1    Garcia-Planella, E.2    Bernal, I.3    Rosinach, M.4    Cabrie, E.5    Fluvia, L.6    Boix, J.7    Gassull, M.A.8
  • 86
    • 84856163835 scopus 로고    scopus 로고
    • Adalimumab Induces and Maintains Clinical Remission in Patients with Moderate-to-Severe Ulcerative Colitis
    • Sandborn WJ, Van Assche G, Reinisch W, et al,. Adalimumab Induces and Maintains Clinical Remission in Patients with Moderate-to-Severe Ulcerative Colitis. Gastroenterology 2012; 142: 257-65.e1-3.
    • (2012) Gastroenterology , vol.142
    • Sandborn, W.J.1    Van Assche, G.2    Reinisch, W.3
  • 87
    • 33645958908 scopus 로고    scopus 로고
    • Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: A randomized placebo-controlled trial
    • Lemann M, Mary JY, Duclos B, et al,. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130: 1054-61.
    • (2006) Gastroenterology , vol.130 , pp. 1054-1061
    • Lemann, M.1    Mary, J.Y.2    Duclos, B.3
  • 88
    • 77950988234 scopus 로고    scopus 로고
    • Infliximab, azathioprine, or combination therapy for Crohn's disease
    • Colombel JF, Sandborn WJ, Reinisch W, et al,. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
    • (2010) N Engl J Med , vol.362 , pp. 1383-1395
    • Colombel, J.F.1    Sandborn, W.J.2    Reinisch, W.3
  • 89
    • 75449114677 scopus 로고    scopus 로고
    • Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease
    • Baert F, Moortgat L, Van Assche G, et al,. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138: 463-8.
    • (2010) Gastroenterology , vol.138 , pp. 463-468
    • Baert, F.1    Moortgat, L.2    Van Assche, G.3
  • 90
    • 34547503869 scopus 로고    scopus 로고
    • Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based Cohort
    • DOI 10.1053/j.gastro.2007.05.051, PII S001650850701102X
    • Froslie KF, Jahnsen J, Moum BA, et al,. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-22. (Pubitemid 47187355)
    • (2007) Gastroenterology , vol.133 , Issue.2 , pp. 412-422
    • Froslie, K.F.1    Jahnsen, J.2    Moum, B.A.3    Vatn, M.H.4
  • 91
    • 70350172248 scopus 로고    scopus 로고
    • Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease
    • Schnitzler F, Fidder H, Ferrante M, et al,. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009; 15: 1295-301.
    • (2009) Inflamm Bowel Dis , vol.15 , pp. 1295-1301
    • Schnitzler, F.1    Fidder, H.2    Ferrante, M.3
  • 92
    • 33846950349 scopus 로고    scopus 로고
    • Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists
    • Lee HH, Song IH, Friedrich M, et al,. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007; 156: 486-91.
    • (2007) Br J Dermatol , vol.156 , pp. 486-491
    • Lee, H.H.1    Song, I.H.2    Friedrich, M.3
  • 93
    • 70350049105 scopus 로고    scopus 로고
    • Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors
    • Exarchou SA, Voulgari PV, Markatseli TE, et al,. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol 2009; 38: 328-31.
    • (2009) Scand J Rheumatol , vol.38 , pp. 328-331
    • Exarchou, S.A.1    Voulgari, P.V.2    Markatseli, T.E.3
  • 94
    • 67650227459 scopus 로고    scopus 로고
    • Dermatological complications and safety of anti-TNF treatments
    • Kerbleski JF, Gottlieb AB,. Dermatological complications and safety of anti-TNF treatments. Gut 2009; 58: 1033-9.
    • (2009) Gut , vol.58 , pp. 1033-1039
    • Kerbleski, J.F.1    Gottlieb, A.B.2
  • 95
    • 0034268094 scopus 로고    scopus 로고
    • Long term safety of infliximab
    • Schaible TF,. Long term safety of infliximab. Can J Gastroenterol. 2000; 14 (Suppl. C): 29C-32C.
    • (2000) Can J Gastroenterol , vol.14 , Issue.SUPPL. C
    • Schaible, T.F.1
  • 96
    • 0037640033 scopus 로고    scopus 로고
    • Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy
    • DOI 10.1159/000069965
    • Devos SA, Van Den Bossche N, De Vos M, et al,. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 2003; 206: 388-90. (Pubitemid 36677038)
    • (2003) Dermatology , vol.206 , Issue.4 , pp. 388-390
    • Devos, S.A.1    Van Den Bossche, N.2    De Vos, M.3    Naeyaert, J.M.4
  • 97
    • 0036149052 scopus 로고    scopus 로고
    • Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis
    • DOI 10.1136/gut.0780047..
    • Chan AT, Cleeve V, Daymond TJ,. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J 2002; 78: 47-8. (Pubitemid 34074917)
    • (2002) Postgraduate Medical Journal , vol.78 , Issue.915 , pp. 47-48
    • Chan, A.T.Y.1    Cleeve, V.2    Daymond, T.J.3
  • 104
    • 0032741665 scopus 로고    scopus 로고
    • The paradigm of Th1 and Th2 cytokines: Its relevance to autoimmunity and allergy
    • Singh VK, Mehrotra S, Agarwal SS,. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res 1999; 20: 147-61.
    • (1999) Immunol Res , vol.20 , pp. 147-161
    • Singh, V.K.1    Mehrotra, S.2    Agarwal, S.S.3
  • 105
    • 27744533607 scopus 로고    scopus 로고
    • Proinflammatory cytokine (IL-1β, IL-6, IL-12, IL-18 and TNF-α) levels in sera of patients with subacute cutaneous lupus erythematosus (SCLE)
    • DOI 10.1016/j.imlet.2005.08.001, PII S0165247805001860
    • Maczynska I, Millo B, Ratajczak-Stefanska V, et al,. Proinflammatory cytokine (IL-1beta, IL-6, IL-12, IL-18 and TNF-alpha) levels in sera of patients with subacute cutaneous lupus erythematosus (SCLE). Immunol Lett 2006; 102: 79-82. (Pubitemid 41606043)
    • (2006) Immunology Letters , vol.102 , Issue.1 , pp. 79-82
    • Maczynska, I.1    Millo, B.2    Ratajczak-Stefanska, V.3    Maleszka, R.4    Szych, Z.5    Kurpisz, M.6    Giedrys-Kalemba, S.7
  • 109
    • 0033763979 scopus 로고    scopus 로고
    • Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: Findings in open-label and randomized placebo-controlled trials
    • Charles PJ, Smeenk RJ, De Jong J, et al,. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43: 2383-90.
    • (2000) Arthritis Rheum , vol.43 , pp. 2383-2390
    • Charles, P.J.1    Smeenk, R.J.2    De Jong, J.3
  • 112
    • 27644548981 scopus 로고    scopus 로고
    • Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease
    • DOI 10.1097/01.MIB.0000186408.07769.78
    • Nancey S, Blanvillain E, Parmentier B, et al,. Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease. Inflamm Bowel Dis 2005; 11: 986-91. (Pubitemid 41580012)
    • (2005) Inflammatory Bowel Diseases , vol.11 , Issue.11 , pp. 986-991
    • Nancey, S.1    Blanvillain, E.2    Parmentier, B.3    Flourie, B.4    Bayet, C.5    Bienvenu, J.6    Fabien, N.7
  • 113
    • 84885138602 scopus 로고    scopus 로고
    • Centocor. Inquiry Number 1-729933475. Published 26 January 2009, and released to authors
    • Centocor. Inquiry Number 1-729933475. Published 26 January 2009, and released to authors.
  • 114
    • 47049112010 scopus 로고    scopus 로고
    • The role of tumor necrosis factor-alpha in systemic lupus erythematosus
    • Aringer M, Smolen JS,. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 2008; 10: 202.
    • (2008) Arthritis Res Ther , vol.10 , pp. 202
    • Aringer, M.1    Smolen, J.S.2
  • 116
    • 71449111969 scopus 로고    scopus 로고
    • Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic
    • Wetter DA, Davis MD,. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009; 84: 979-84.
    • (2009) Mayo Clin Proc , vol.84 , pp. 979-984
    • Wetter, D.A.1    Davis, M.D.2
  • 117
    • 78650110438 scopus 로고    scopus 로고
    • Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent
    • Subramanian S, Yajnik V, Sands BE, et al,. Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis 2011; 17: 99-104.
    • (2011) Inflamm Bowel Dis , vol.17 , pp. 99-104
    • Subramanian, S.1    Yajnik, V.2    Sands, B.E.3
  • 119
    • 33745064418 scopus 로고    scopus 로고
    • Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
    • Schiff MH, Burmester GR, Kent JD, et al,. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 889-94.
    • (2006) Ann Rheum Dis , vol.65 , pp. 889-894
    • Schiff, M.H.1    Burmester, G.R.2    Kent, J.D.3
  • 120
    • 84885107701 scopus 로고    scopus 로고
    • FDA. US Food and Drug Administration. FDA labels for TNF inhibitors: infliximab http://www.fda. gov/cder/foi/label /2008/125057s114lbl.pdf; etanercept, http://www.fda.gov/cder/foi/ label/2008/103795s5359lbl.pdf; andcertolizumab pegol, http://www.cimzia.com/ pdf/CIMZIA%20PI%20032008.pdf. Accessed November 1, 2008
    • FDA. US Food and Drug Administration. FDA labels for TNF inhibitors: infliximab. Available at: http://www.fda.gov/cder/foi/label/2007/103772s5189lbl. pdf; adalimumab, http://www.fda.gov/cder/foi/label/2008/125057s114lbl.pdf; etanercept, http://www.fda.gov/cder/foi/label/2008/103795s5359lbl.pdf; andcertolizumab pegol, http://www.cimzia.com/pdf/CIMZIA%20PI%20032008.pdf. Accessed November 1, 2008.
  • 121
    • 21744446004 scopus 로고    scopus 로고
    • Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: A French national survey
    • De Bandt M, Sibilia J, Le Loet X, et al,. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005; 7: R545-51.
    • (2005) Arthritis Res Ther , vol.7
    • De Bandt, M.1    Sibilia, J.2    Le Loet, X.3
  • 122
    • 44349171691 scopus 로고    scopus 로고
    • Drug-Induced Lupus due to Anti-Tumor Necrosis Factor α Agents
    • DOI 10.1016/j.semarthrit.2007.08.003, PII S0049017207001394
    • Costa MF, Said NR, Zimmermann B,. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008; 37: 381-7. (Pubitemid 351734520)
    • (2008) Seminars in Arthritis and Rheumatism , vol.37 , Issue.6 , pp. 381-387
    • Costa, M.F.1    Said, N.R.2    Zimmermann, B.3
  • 123
    • 0020056755 scopus 로고
    • Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis
    • Yates VM, Watkinson G, Kelman A,. Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. Br J Dermatol 1982; 106: 323-30. (Pubitemid 12177002)
    • (1982) British Journal of Dermatology , vol.106 , Issue.3 , pp. 323-330
    • Yates, V.M.1    Watkinson, G.2    Kelman, A.3
  • 124
    • 77949865934 scopus 로고    scopus 로고
    • The status of biologic therapies in the treatment of moderate to severe psoriasis
    • Menter A,. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis 2009; 84: 14-24.
    • (2009) Cutis , vol.84 , pp. 14-24
    • Menter, A.1
  • 125
    • 77955924889 scopus 로고    scopus 로고
    • Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis
    • Menter A, Gordon KB, Leonardi CL, et al,. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol 2010; 63: 448-56.
    • (2010) J Am Acad Dermatol , vol.63 , pp. 448-456
    • Menter, A.1    Gordon, K.B.2    Leonardi, C.L.3
  • 127
    • 63849102069 scopus 로고    scopus 로고
    • Review article: Anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease
    • Fiorino G, Allez M, Malesci A, et al,. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009; 29: 921-7.
    • (2009) Aliment Pharmacol Ther , vol.29 , pp. 921-927
    • Fiorino, G.1    Allez, M.2    Malesci, A.3
  • 128
    • 61949136505 scopus 로고    scopus 로고
    • First case report of adalimumab-induced psoriasis in Crohn's disease
    • Harris MD, Richards R,. First case report of adalimumab-induced psoriasis in Crohn's disease. Am J Gastroenterol 2009; 104: 792-3.
    • (2009) Am J Gastroenterol , vol.104 , pp. 792-793
    • Harris, M.D.1    Richards, R.2
  • 129
    • 77957108223 scopus 로고    scopus 로고
    • Psoriatic skin lesions induced by certolizumab pegol
    • Klein RQ, Spivack J, Choate KA,. Psoriatic skin lesions induced by certolizumab pegol. Arch Dermatol 2010; 146: 1055-6.
    • (2010) Arch Dermatol , vol.146 , pp. 1055-1056
    • Klein, R.Q.1    Spivack, J.2    Choate, K.A.3
  • 130
    • 72049122955 scopus 로고    scopus 로고
    • Severe cutaneous psoriasis after certolizumab pegol treatment: Report of a case
    • Mocciaro F, Renna S, Orlando A, et al,. Severe cutaneous psoriasis after certolizumab pegol treatment: report of a case. Am J Gastroenterol 2009; 104: 2867-8.
    • (2009) Am J Gastroenterol , vol.104 , pp. 2867-2868
    • Mocciaro, F.1    Renna, S.2    Orlando, A.3
  • 131
    • 58849160468 scopus 로고    scopus 로고
    • Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: Results from the British Society for Rheumatology Biologics Register
    • Harrison MJ, Dixon WG, Watson KD, et al,. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68: 209-15.
    • (2009) Ann Rheum Dis , vol.68 , pp. 209-215
    • Harrison, M.J.1    Dixon, W.G.2    Watson, K.D.3
  • 132
    • 0042887352 scopus 로고    scopus 로고
    • Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: A new perspective on the role of host defence in the pathogenesis of the disease?
    • DOI 10.1136/ard.62.9.829
    • Baeten D, Kruithof E, Van den Bosch F, et al,. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003; 62: 829-34. (Pubitemid 37026492)
    • (2003) Annals of the Rheumatic Diseases , vol.62 , Issue.9 , pp. 829-834
    • Baeten, D.1    Kruithof, E.2    Van Den Bosch, F.3    Van Den Bossche, N.4    Herssens, A.5    Mielants, H.6    De Keyser, F.7    Veys, E.M.8
  • 133
    • 81355151359 scopus 로고    scopus 로고
    • Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: A new series and a review of 120 cases from the literature
    • Cullen G, Kroshinsky D, Cheifetz AS, et al,. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011; 34: 1318-27.
    • (2011) Aliment Pharmacol Ther , vol.34 , pp. 1318-1327
    • Cullen, G.1    Kroshinsky, D.2    Cheifetz, A.S.3
  • 134
    • 42749088023 scopus 로고    scopus 로고
    • Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy
    • Wendling D, Balblanc JC, Briancon D, et al,. Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy. Joint Bone Spine 2008; 75: 315-8.
    • (2008) Joint Bone Spine , vol.75 , pp. 315-318
    • Wendling, D.1    Balblanc, J.C.2    Briancon, D.3
  • 136
    • 37249030025 scopus 로고    scopus 로고
    • Psoriasiform eruptions during anti-TNF-α treatment: Psoriasis or not? [5]
    • DOI 10.1001/archderm.143.12.1593
    • Seneschal J, Lepreux S, Milpied B, et al,. Psoriasiform eruptions during anti TNF-alpha treatment: psoriasis or not? Arch Dermatol 2007; 143: 1593-5; author reply 1595. (Pubitemid 350277789)
    • (2007) Archives of Dermatology , vol.143 , Issue.12 , pp. 1593-1595
    • Seneschal, J.1    Lepreux, S.2    Milpied, B.3    Schaeverbeke, T.4    Taieb, A.5
  • 137
    • 36048994573 scopus 로고    scopus 로고
    • Triggering psoriasis: The role of infections and medications
    • DOI 10.1016/j.clindermatol.2007.08.015, PII S0738081X07001599
    • Fry L, Baker BS,. Triggering psoriasis: the role of infections and medications. Clin Dermatol 2007; 25: 606-15. (Pubitemid 350087607)
    • (2007) Clinics in Dermatology , vol.25 , Issue.6 , pp. 606-615
    • Fry, L.1    Baker, B.S.2
  • 138
    • 47949126329 scopus 로고    scopus 로고
    • Psoriasiform lesions induced by tumour necrosis factor antagonists: A skin-deep medical conundrum
    • Carter JD, Gerard HC, Hudson AP,. Psoriasiform lesions induced by tumour necrosis factor antagonists: a skin-deep medical conundrum. Ann Rheum Dis 2008; 67: 1181-3.
    • (2008) Ann Rheum Dis , vol.67 , pp. 1181-1183
    • Carter, J.D.1    Gerard, H.C.2    Hudson, A.P.3
  • 141
    • 33847279025 scopus 로고    scopus 로고
    • Pathogenesis and therapy of psoriasis
    • Lowes MA, Bowcock AM, Krueger JG,. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-73.
    • (2007) Nature , vol.445 , pp. 866-873
    • Lowes, M.A.1    Bowcock, A.M.2    Krueger, J.G.3
  • 143
    • 31144441631 scopus 로고    scopus 로고
    • In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: Enhanced expression in psoriatic skin
    • Piskin G, Sylva-Steenland RM, Bos JD, et al,. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006; 176: 1908-15. (Pubitemid 43134336)
    • (2006) Journal of Immunology , vol.176 , Issue.3 , pp. 1908-1915
    • Piskin, G.1    Sylva-Steenland, R.M.R.2    Bos, J.D.3    Teunissen, M.B.M.4
  • 144
    • 78649445740 scopus 로고    scopus 로고
    • Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis
    • Collamer AN, Battafarano DF,. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010; 40: 233-40.
    • (2010) Semin Arthritis Rheum , vol.40 , pp. 233-240
    • Collamer, A.N.1    Battafarano, D.F.2
  • 145
    • 47249159958 scopus 로고    scopus 로고
    • Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action
    • DOI 10.1002/art.23835
    • Collamer AN, Guerrero KT, Henning JS, et al,. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008; 59: 996-1001. (Pubitemid 351990997)
    • (2008) Arthritis Care and Research , vol.59 , Issue.7 , pp. 996-1001
    • Collamer, A.N.1    Guerrero, K.T.2    Henning, J.S.3    Battafarano, D.F.4
  • 146
    • 67650216399 scopus 로고    scopus 로고
    • Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases
    • Ko JM, Gottlieb AB, Kerbleski JF,. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat. 2009; 20: 100-8.
    • (2009) J Dermatolog Treat. , vol.20 , pp. 100-108
    • Ko, J.M.1    Gottlieb, A.B.2    Kerbleski, J.F.3
  • 147
    • 84860835230 scopus 로고    scopus 로고
    • Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: A report of 21 cases
    • Guerra I, Algaba A, Perez-Calle JL, et al,. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. Journal of Crohn's and Colitis 2012; 6: 518-23.
    • (2012) Journal of Crohn's and Colitis , vol.6 , pp. 518-523
    • Guerra, I.1    Algaba, A.2    Perez-Calle, J.L.3
  • 148
    • 79952818972 scopus 로고    scopus 로고
    • Psoriatic alopecia/alopecia areata-like reactions secondary to anti-tumor necrosis factor-alpha therapy: A novel cause of noncicatricial alopecia
    • Doyle LA, Sperling LC, Baksh S, et al,. Psoriatic alopecia/alopecia areata-like reactions secondary to anti-tumor necrosis factor-alpha therapy: a novel cause of noncicatricial alopecia. Am J Dermatopathol 2011; 33: 161-6.
    • (2011) Am J Dermatopathol , vol.33 , pp. 161-166
    • Doyle, L.A.1    Sperling, L.C.2    Baksh, S.3
  • 149
    • 73949130344 scopus 로고    scopus 로고
    • Adalimumab-induced psoriasis of the scalp with diffuse alopecia: A severe potentially irreversible cutaneous side effect of TNF-alpha blockers
    • El Shabrawi-Caelen L, La Placa M, Vincenzi C, et al,. Adalimumab-induced psoriasis of the scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers. Inflamm Bowel Dis 2010; 16: 182-3.
    • (2010) Inflamm Bowel Dis , vol.16 , pp. 182-183
    • El Shabrawi-Caelen, L.1    La Placa, M.2    Vincenzi, C.3
  • 150
    • 41049110226 scopus 로고    scopus 로고
    • Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis
    • DOI 10.1007/s00296-007-0475-6
    • Lee YH, Woo JH, Rho YH, et al,. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatol Int 2008; 28: 553-9. (Pubitemid 351422618)
    • (2008) Rheumatology International , vol.28 , Issue.6 , pp. 553-559
    • Lee, Y.H.1    Woo, J.H.2    Rho, Y.H.3    Choi, S.J.4    Ji, J.D.5    Song, G.G.6
  • 152
    • 66949122526 scopus 로고    scopus 로고
    • Lichen planus-like eruptions: An emerging side effect of tumor necrosis factor-alpha antagonists
    • Asarch A, Gottlieb AB, Lee J, et al,. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol 2009; 61: 104-11.
    • (2009) J Am Acad Dermatol , vol.61 , pp. 104-111
    • Asarch, A.1    Gottlieb, A.B.2    Lee, J.3
  • 153
    • 24944532440 scopus 로고    scopus 로고
    • Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: A prospective study
    • Flendrie M, Vissers WH, Creemers MC, et al,. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005; 7: R666-76.
    • (2005) Arthritis Res Ther. , vol.7
    • Flendrie, M.1    Vissers, W.H.2    Creemers, M.C.3
  • 155
    • 53549113693 scopus 로고    scopus 로고
    • Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximab
    • 829
    • Moss AC, Treister NS, Marsee DK, et al,. Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximab. Gastroenterology 2007; 132: 488, 829.
    • (2007) Gastroenterology , vol.132 , pp. 488
    • Moss, A.C.1    Treister, N.S.2    Marsee, D.K.3
  • 156
    • 36849042016 scopus 로고    scopus 로고
    • Lichen planus associated with etanercept
    • Battistella M, Rivet J, Bachelez H, et al,. Lichen planus associated with etanercept. Br J Dermatol 2008; 158: 188-90.
    • (2008) Br J Dermatol , vol.158 , pp. 188-190
    • Battistella, M.1    Rivet, J.2    Bachelez, H.3
  • 159
    • 34250677788 scopus 로고    scopus 로고
    • Etanercept for the management of oral lichen planus
    • Yarom N,. Etanercept for the management of oral lichen planus. Am J Clin Dermatol 2007; 8: 121. (Pubitemid 46998557)
    • (2007) American Journal of Clinical Dermatology , vol.8 , Issue.2 , pp. 121
    • Yarom, N.1
  • 160
    • 0037709396 scopus 로고    scopus 로고
    • Atopic dermatitis-like eruption precipitated by infliximab [4]
    • Wright RC,. Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol 2003; 49: 160-1. (Pubitemid 36801660)
    • (2003) Journal of the American Academy of Dermatology , vol.49 , Issue.1 , pp. 160-161
    • Wright, R.C.1
  • 161
    • 80051489321 scopus 로고    scopus 로고
    • Tumor necrosis factor-alpha in vitiligo: Direct correlation between tissue levels and clinical parameters
    • Kim NH, Torchia D, Rouhani P, et al,. Tumor necrosis factor-alpha in vitiligo: direct correlation between tissue levels and clinical parameters. Cutan Ocul Toxicol. 2011; 30: 225-7.
    • (2011) Cutan Ocul Toxicol. , vol.30 , pp. 225-227
    • Kim, N.H.1    Torchia, D.2    Rouhani, P.3
  • 162
    • 80053552817 scopus 로고    scopus 로고
    • Worsening of vitiligo and onset of new psoriasiform dermatitis following treatment with infliximab
    • Alghamdi KM, Khurrum H, Rikabi A,. Worsening of vitiligo and onset of new psoriasiform dermatitis following treatment with infliximab. J Cutan Med Surg. 2011; 15: 280-4.
    • (2011) J Cutan Med Surg. , vol.15 , pp. 280-284
    • Alghamdi, K.M.1    Khurrum, H.2    Rikabi, A.3
  • 164
    • 42949160630 scopus 로고    scopus 로고
    • Acneiform eruption following anti-TNF-alpha treatment: A report of three cases
    • Sun G, Wasko CA, Hsu S,. Acneiform eruption following anti-TNF-alpha treatment: a report of three cases. J Drugs Dermatol 2008; 7: 69-71.
    • (2008) J Drugs Dermatol , vol.7 , pp. 69-71
    • Sun, G.1    Wasko, C.A.2    Hsu, S.3
  • 165
    • 0038772008 scopus 로고    scopus 로고
    • Tumor necrosis factor biology in experimental and clinical arthritis
    • DOI 10.1097/00002281-200307000-00003
    • Sfikakis PP, Kollias G,. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol 2003; 15: 380-6. (Pubitemid 36774248)
    • (2003) Current Opinion in Rheumatology , vol.15 , Issue.4 , pp. 380-386
    • Sfikakis, P.P.1    Kollias, G.2
  • 167
    • 84866387410 scopus 로고    scopus 로고
    • Vasculitis Associated with Tumor Necrosis Factor-alpha Inhibitors
    • Sokumbi O, Wetter DA, Makol A, et al,. Vasculitis Associated With Tumor Necrosis Factor-alpha Inhibitors. Mayo Clin Proc 2012; 87: 739-45.
    • (2012) Mayo Clin Proc , vol.87 , pp. 739-745
    • Sokumbi, O.1    Wetter, D.A.2    Makol, A.3
  • 170
    • 31444454494 scopus 로고    scopus 로고
    • A ring-shaped eruption
    • DOI 10.1016/j.amjmed.2005.12.002, PII S000293430501137X
    • Alexander JS, Paniker PU,. A ring-shaped eruption. Am J Med 2006; 119: 125-7. (Pubitemid 43151476)
    • (2006) American Journal of Medicine , vol.119 , Issue.2 , pp. 125-127
    • Alexander, J.S.1    Paniker, P.2
  • 172
    • 73449120738 scopus 로고    scopus 로고
    • Education and imaging. Gastrointestinal: Improvement of granuloma annulare with anti-tumour necrosis factor alpha therapy for Crohn's disease
    • Fanning SB, Chapman G, Yau Y, et al,. Education and imaging. Gastrointestinal: improvement of granuloma annulare with anti-tumour necrosis factor alpha therapy for Crohn's disease. J Gastroenterol Hepatol 2010; 25: 215.
    • (2010) J Gastroenterol Hepatol , vol.25 , pp. 215
    • Fanning, S.B.1    Chapman, G.2    Yau, Y.3
  • 173
    • 0031881853 scopus 로고    scopus 로고
    • The interstitial granulomatous drug reaction: A distinctive clinical and pathological entity
    • DOI 10.1111/j.1600-0560.1998.tb01693.x
    • Magro CM, Crowson AN, Schapiro BL,. The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity. J Cutan Pathol 1998; 25: 72-8. (Pubitemid 28073644)
    • (1998) Journal of Cutaneous Pathology , vol.25 , Issue.2 , pp. 72-78
    • Magro, C.M.1    Crowson, A.N.2    Schapiro, B.L.3
  • 177
    • 0030023290 scopus 로고    scopus 로고
    • Granuloma annulare and necrobiosis lipoidica tissue reactions as a manifestation of systemic disease
    • DOI 10.1016/S0046-8177(96)90137-9
    • Magro CM, Crowson AN, Regauer S,. Granuloma annulare and necrobiosis lipoidica tissue reactions as a manifestation of systemic disease. Hum Pathol 1996; 27: 50-6. (Pubitemid 26015580)
    • (1996) Human Pathology , vol.27 , Issue.1 , pp. 50-56
    • Magro, C.M.1    Crowson, A.N.2    Regauer, S.3
  • 178
    • 0036621140 scopus 로고    scopus 로고
    • Interstitial granulomatous dermatitis with plaques
    • Tomasini C, Pippione M,. Interstitial granulomatous dermatitis with plaques. J Am Acad Dermatol 2002; 46: 892-9.
    • (2002) J Am Acad Dermatol , vol.46 , pp. 892-899
    • Tomasini, C.1    Pippione, M.2
  • 179
    • 0028089859 scopus 로고
    • The histopathologic spectrum of palisaded neutrophilic and granulomatous dermatitis in patients with collagen vascular disease
    • DOI 10.1001/archderm.130.10.1278
    • Chu P, Connolly MK, LeBoit PE,. The histopathologic spectrum of palisaded neutrophilic and granulomatous dermatitis in patients with collagen vascular disease. Arch Dermatol 1994; 130: 1278-83. (Pubitemid 24313287)
    • (1994) Archives of Dermatology , vol.130 , Issue.10 , pp. 1278-1283
    • Chu, P.1    Connolly, M.K.2    LeBoit, P.E.3
  • 181
    • 84855254283 scopus 로고    scopus 로고
    • Interstitial granulomatous dermatitis: Another clinical variant
    • Patsatsi A, Kyriakou A, Triantafyllidou E, et al,. Interstitial granulomatous dermatitis: another clinical variant. Case Rep Dermatol. 2011; 3: 195-200.
    • (2011) Case Rep Dermatol. , vol.3 , pp. 195-200
    • Patsatsi, A.1    Kyriakou, A.2    Triantafyllidou, E.3
  • 183
    • 0031867753 scopus 로고    scopus 로고
    • Accelerated cutaneous nodulosis during methotrexate therapy in a patient with rheumatoid arthritis
    • Williams FM, Cohen PR, Arnett FC,. Accelerated cutaneous nodulosis during methotrexate therapy in a patient with rheumatoid arthritis. J Am Acad Dermatol 1998; 39: 359-62. (Pubitemid 28367316)
    • (1998) Journal of the American Academy of Dermatology , vol.39 , Issue.2 , pp. 359-362
    • Williams, F.M.1    Cohen, P.R.2    Arnett, F.C.3
  • 185
    • 72949115077 scopus 로고    scopus 로고
    • Interstitial granulomatous dermatitis in rheumatoid arthritis responsive to etanercept
    • Zoli A, Massi G, Pinnelli M, et al,. Interstitial granulomatous dermatitis in rheumatoid arthritis responsive to etanercept. Clin Rheumatol 2010; 29: 99-101.
    • (2010) Clin Rheumatol , vol.29 , pp. 99-101
    • Zoli, A.1    Massi, G.2    Pinnelli, M.3
  • 186
    • 10444238497 scopus 로고    scopus 로고
    • Palisaded neutrophilic and granulomatous dermatitis: An unusual cutaneous manifestation of immune-mediated disorders
    • DOI 10.1016/j.semarthrit.2004.06.001, PII S0049017204001337
    • Bremner R, Simpson E, White CR, et al,. Palisaded neutrophilic and granulomatous dermatitis: an unusual cutaneous manifestation of immune-mediated disorders. Semin Arthritis Rheum 2004; 34: 610-6. (Pubitemid 39643123)
    • (2004) Seminars in Arthritis and Rheumatism , vol.34 , Issue.3 , pp. 610-616
    • Bremner, R.1    Simpson, E.2    White Jr., C.R.3    Morrison, L.4    Deodhar, A.5
  • 189
    • 47149092108 scopus 로고    scopus 로고
    • Skin manifestations of inflammatory bowel disease
    • DOI 10.1016/j.clindermatol.2007.10.018, PII S0738081X07002416
    • Timani S, Mutasim DF,. Skin manifestations of inflammatory bowel disease. Clin Dermatol 2008; 26: 265-73. (Pubitemid 351978196)
    • (2008) Clinics in Dermatology , vol.26 , Issue.3 , pp. 265-273
    • Timani, S.1    Mutasim, D.F.2
  • 191
    • 0035044890 scopus 로고    scopus 로고
    • The prevalence of extraintestinal diseases in inflammatory bowel disease: A population-based study
    • DOI 10.1016/S0002-9270(01)02319-X, PII S000292700102319X
    • Bernstein CN, Blanchard JF, Rawsthorne P, et al,. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001; 96: 1116-22. (Pubitemid 32319146)
    • (2001) American Journal of Gastroenterology , vol.96 , Issue.4 , pp. 1116-1122
    • Bernstein, C.N.1    Blanchard, J.F.2    Rawsthorne, P.3    Yu, N.4
  • 192
    • 0027193194 scopus 로고
    • Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients
    • Farmer RG, Easley KA, Rankin GB,. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci 1993; 38: 1137-46. (Pubitemid 23175139)
    • (1993) Digestive Diseases and Sciences , vol.38 , Issue.6 , pp. 1137-1146
    • Farmer, R.G.1    Easley, K.A.2    Rankin, G.B.3
  • 193
    • 67650137726 scopus 로고    scopus 로고
    • Mucocutaneous manifestations in inflammatory bowel disease
    • Yuksel I, Basar O, Ataseven H, et al,. Mucocutaneous manifestations in inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 546-50.
    • (2009) Inflamm Bowel Dis , vol.15 , pp. 546-550
    • Yuksel, I.1    Basar, O.2    Ataseven, H.3
  • 196
    • 84873622497 scopus 로고    scopus 로고
    • Drug-induced erythema nodosum after the administration of certolizumab in Crohn's disease
    • Biedermann L, Kerl K, Rogler G, et al,. Drug-induced erythema nodosum after the administration of certolizumab in Crohn's disease. Inflamm Bowel Dis 2013; 19: E4-6.
    • (2013) Inflamm Bowel Dis , vol.19
    • Biedermann, L.1    Kerl, K.2    Rogler, G.3
  • 197
    • 43449131274 scopus 로고    scopus 로고
    • Erythema nodosum associated with infliximab therapy
    • Rosen T, Martinelli P,. Erythema nodosum associated with infliximab therapy. Dermatol Online J 2008; 14: 3.
    • (2008) Dermatol Online J , vol.14 , pp. 3
    • Rosen, T.1    Martinelli, P.2
  • 198
    • 35648973826 scopus 로고    scopus 로고
    • Psoriasis, erythema nodosum, and nummular eczema onset in an ankylosing spondylitis patient treated with infliximab [2]
    • DOI 10.1080/03009740701288173, PII 783464666
    • Delle Sedie A, Bazzichi L, Bombardieri S, et al,. Psoriasis, erythema nodosum, and nummular eczema onset in an ankylosing spondylitis patient treated with infliximab. Scand J Rheumatol 2007; 36: 403-4. (Pubitemid 350034813)
    • (2007) Scandinavian Journal of Rheumatology , vol.36 , Issue.5 , pp. 403-404
    • Sedie, A.D.1    Bazzichi, L.2    Bombardieri, S.3    Riente, L.4
  • 199
    • 1542329560 scopus 로고    scopus 로고
    • Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Behçet's disease [7]
    • DOI 10.1093/rheumatology/keh056
    • Yucel AE, Kart-Koseoglu H, Akova YA, et al,. Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Behcet's disease. Rheumatology (Oxford) 2004; 43: 394-6. (Pubitemid 38313200)
    • (2004) Rheumatology , vol.43 , Issue.3 , pp. 394-396
    • Yucel, A.E.1    Kart-Koseoglu, H.2    Akova, Y.A.3    Demirhan, B.4    Boyacioglu, S.5
  • 200
    • 33646696885 scopus 로고    scopus 로고
    • Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
    • DOI 10.1001/jama.295.19.2275
    • Bongartz T, Sutton AJ, Sweeting MJ, et al,. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85. (Pubitemid 43736578)
    • (2006) Journal of the American Medical Association , vol.295 , Issue.19 , pp. 2275-2285
    • Bongartz, T.1    Sutton, A.J.2    Sweeting, M.J.3    Buchan, I.4    Matteson, E.L.5    Montori, V.6
  • 201
    • 78751685797 scopus 로고    scopus 로고
    • Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: Meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data
    • Askling J, Fahrbach K, Nordstrom B, et al,. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011; 20: 119-30.
    • (2011) Pharmacoepidemiol Drug Saf , vol.20 , pp. 119-130
    • Askling, J.1    Fahrbach, K.2    Nordstrom, B.3
  • 202
    • 82255175193 scopus 로고    scopus 로고
    • Cutaneous lymphoma in a patient with ulcerative colitis after immunosuppressive therapy
    • Rojas-Feria M, Eslam M, Castro-Fernandez M, et al,. Cutaneous lymphoma in a patient with ulcerative colitis after immunosuppressive therapy. J Crohns Colitis 2011; 5: 608-11.
    • (2011) J Crohns Colitis , vol.5 , pp. 608-611
    • Rojas-Feria, M.1    Eslam, M.2    Castro-Fernandez, M.3
  • 203
    • 82955195113 scopus 로고    scopus 로고
    • Role of Thiopurine and Anti-TNF Therapy in Lymphoma in Inflammatory Bowel Disease
    • Herrinton LJ, Liu L, Weng X, et al,. Role of Thiopurine and Anti-TNF Therapy in Lymphoma in Inflammatory Bowel Disease. Am J Gastroenterol 2011; 106: 2146-53.
    • (2011) Am J Gastroenterol , vol.106 , pp. 2146-2153
    • Herrinton, L.J.1    Liu, L.2    Weng, X.3
  • 204
    • 0036675378 scopus 로고    scopus 로고
    • Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis
    • author reply 2259
    • Kent PD, Davis JM 3rd, Davis MD, et al,. Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. Arthritis Rheum 2002; 46: 2257-8; author reply 2259.
    • (2002) Arthritis Rheum , vol.46 , pp. 2257-2258
    • Kent, P.D.1    Davis III, J.M.2    Davis, M.D.3
  • 205
    • 77956386272 scopus 로고    scopus 로고
    • Development of pyoderma gangrenosum during therapy with infliximab
    • Jaimes-Lopez N, Molina V, Arroyave JE, et al,. Development of pyoderma gangrenosum during therapy with infliximab. J Dermatol Case Rep 2009; 3: 20-3.
    • (2009) J Dermatol Case Rep , vol.3 , pp. 20-23
    • Jaimes-Lopez, N.1    Molina, V.2    Arroyave, J.E.3
  • 210
    • 33644605483 scopus 로고    scopus 로고
    • Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy
    • Yousry TA, Major EO, Ryschkewitsch C, et al,. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354: 924-33.
    • (2006) N Engl J Med , vol.354 , pp. 924-933
    • Yousry, T.A.1    Major, E.O.2    Ryschkewitsch, C.3
  • 212
    • 34548602366 scopus 로고    scopus 로고
    • Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies
    • DOI 10.1001/archneur.64.9.1331
    • Krumbholz M, Pellkofer H, Gold R, et al,. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol 2007; 64: 1331-3. (Pubitemid 47403090)
    • (2007) Archives of Neurology , vol.64 , Issue.9 , pp. 1331-1333
    • Krumbholz, M.1    Pellkofer, H.2    Gold, R.3    Hoffmann, L.A.4    Hohlfeld, R.5    Kumpfel, T.6
  • 213
    • 53049091561 scopus 로고    scopus 로고
    • A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
    • Sandborn WJ, Feagan BG, Fedorak RN, et al,. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008; 135: 1130-41.
    • (2008) Gastroenterology , vol.135 , pp. 1130-1141
    • Sandborn, W.J.1    Feagan, B.G.2    Fedorak, R.N.3
  • 214
    • 84866754101 scopus 로고    scopus 로고
    • Effectiveness and Safety of Ustekinumab as Rescue Therapy in Multi-Drug Resistant Crohn's Disease
    • (Suppl. 1)
    • Ginard D, Khorrami S, Marin-Jimenez I,. Effectiveness and Safety of Ustekinumab as Rescue Therapy in Multi-Drug Resistant Crohn's Disease. Gastroenterology 2012; 142 (Suppl. 1): S-355.
    • (2012) Gastroenterology , vol.142
    • Ginard, D.1    Khorrami, S.2    Marin-Jimenez, I.3
  • 215
    • 43449111187 scopus 로고    scopus 로고
    • Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
    • DOI 10.1016/S0140-6736(08)60725-4, PII S0140673608607254
    • Leonardi CL, Kimball AB, Papp KA, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74. (Pubitemid 351671883)
    • (2008) The Lancet , vol.371 , Issue.9625 , pp. 1665-1674
    • Leonardi, C.L.1    Kimball, A.B.2    Papp, K.A.3    Yeilding, N.4    Guzzo, C.5    Wang, Y.6    Li, S.7    Dooley, L.T.8    Gordon, K.B.9
  • 216
    • 79957519306 scopus 로고    scopus 로고
    • Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis
    • Gregoriou S, Kazakos C, Christofidou E, et al,. Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis. Eur J Dermatol 2011; 21: 104-5.
    • (2011) Eur J Dermatol , vol.21 , pp. 104-105
    • Gregoriou, S.1    Kazakos, C.2    Christofidou, E.3
  • 217
    • 79956034032 scopus 로고    scopus 로고
    • Exacerbation and change of psoriasis morphology in a patient treated with ustekinumab
    • Kerdel FA, Valeron-Almazan P, Vitiello M, et al,. Exacerbation and change of psoriasis morphology in a patient treated with ustekinumab. J Cutan Med Surg 2011; 15: 183-4.
    • (2011) J Cutan Med Surg , vol.15 , pp. 183-184
    • Kerdel, F.A.1    Valeron-Almazan, P.2    Vitiello, M.3
  • 218
    • 80053371455 scopus 로고    scopus 로고
    • Exacerbation of infliximab-induced palmoplantar psoriasis under ustekinumab therapy in a patient with ankylosing spondylitis
    • Safa G, Martin A, Darrieux L,. Exacerbation of infliximab-induced palmoplantar psoriasis under ustekinumab therapy in a patient with ankylosing spondylitis. J Clin Rheumatol. 2011; 17: 385-6.
    • (2011) J Clin Rheumatol. , vol.17 , pp. 385-386
    • Safa, G.1    Martin, A.2    Darrieux, L.3
  • 219
    • 84861079637 scopus 로고    scopus 로고
    • Flare of pustular psoriasis after initiating ustekinumab therapy
    • Wenk KS, Claros JM, Ehrlich A,. Flare of pustular psoriasis after initiating ustekinumab therapy. J Dermatolog Treat. 2012; 23: 212-4.
    • (2012) J Dermatolog Treat. , vol.23 , pp. 212-214
    • Wenk, K.S.1    Claros, J.M.2    Ehrlich, A.3
  • 220
    • 84858633545 scopus 로고    scopus 로고
    • An update on the long-term safety experience of ustekinumab: Results from the psoriasis clinical development program with up to four years of follow-up
    • Reich K, Papp KA, Griffiths CE, et al,. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol 2012; 11: 300-12.
    • (2012) J Drugs Dermatol , vol.11 , pp. 300-312
    • Reich, K.1    Papp, K.A.2    Griffiths, C.E.3
  • 221
    • 84859869815 scopus 로고    scopus 로고
    • Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials
    • Gordon KB, Papp KA, Langley RG, et al,. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol 2012; 66: 742-51.
    • (2012) J Am Acad Dermatol , vol.66 , pp. 742-751
    • Gordon, K.B.1    Papp, K.A.2    Langley, R.G.3
  • 222
    • 84856975715 scopus 로고    scopus 로고
    • The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis
    • Young L, Czarnecki D,. The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis. Australas J Dermatol 2012; 53: 57-60.
    • (2012) Australas J Dermatol , vol.53 , pp. 57-60
    • Young, L.1    Czarnecki, D.2
  • 223
    • 43449139402 scopus 로고    scopus 로고
    • Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
    • DOI 10.1016/S0140-6736(08)60726-6, PII S0140673608607266
    • Papp KA, Langley RG, Lebwohl M, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84. (Pubitemid 351671884)
    • (2008) The Lancet , vol.371 , Issue.9625 , pp. 1675-1684
    • Papp, K.A.1    Langley, R.G.2    Lebwohl, M.3    Krueger, G.G.4    Szapary, P.5    Yeilding, N.6    Guzzo, C.7    Hsu, M.-C.8    Wang, Y.9    Li, S.10    Dooley, L.T.11    Reich, K.12
  • 224
    • 74249094930 scopus 로고    scopus 로고
    • Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis
    • Griffiths CE, Strober BE, van de Kerkhof P, et al,. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-28.
    • (2010) N Engl J Med , vol.362 , pp. 118-128
    • Griffiths, C.E.1    Strober, B.E.2    Van De Kerkhof, P.3
  • 225
    • 79955696994 scopus 로고    scopus 로고
    • Ustekinumab and herpes zoster
    • Failla V, Nikkels AF,. Ustekinumab and herpes zoster. Dermatology 2011; 222: 119-22.
    • (2011) Dermatology , vol.222 , pp. 119-122
    • Failla, V.1    Nikkels, A.F.2
  • 226
    • 84863778808 scopus 로고    scopus 로고
    • Herpes zoster in patients treated with biologicals
    • Failla V, Jacques J, Castronovo C, et al,. Herpes zoster in patients treated with biologicals. Dermatology 2012; 224: 251-6.
    • (2012) Dermatology , vol.224 , pp. 251-256
    • Failla, V.1    Jacques, J.2    Castronovo, C.3
  • 227
    • 77956289560 scopus 로고    scopus 로고
    • Alopecia areata developing parallel to improvement of psoriasis during ustekinumab therapy
    • Slowinska M, Kardynal A, Warszawik O, et al,. Alopecia areata developing parallel to improvement of psoriasis during ustekinumab therapy. J Dermatol Case Rep. 2010; 4: 15-7.
    • (2010) J Dermatol Case Rep. , vol.4 , pp. 15-17
    • Slowinska, M.1    Kardynal, A.2    Warszawik, O.3
  • 228
    • 84865013186 scopus 로고    scopus 로고
    • Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis
    • Sandborn WJ, Ghosh S, Panes J, et al,. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367: 616-24.
    • (2012) N Engl J Med , vol.367 , pp. 616-624
    • Sandborn, W.J.1    Ghosh, S.2    Panes, J.3
  • 229
    • 84866156845 scopus 로고    scopus 로고
    • A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
    • Kremer JM, Cohen S, Wilkinson BE, et al,. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012; 64: 970-81.
    • (2012) Arthritis Rheum , vol.64 , pp. 970-981
    • Kremer, J.M.1    Cohen, S.2    Wilkinson, B.E.3
  • 230
    • 84865587510 scopus 로고    scopus 로고
    • Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: Efficacy, renal function and safety at 1 year
    • Vincenti F, Tedesco Silva H, Busque S, et al,. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant 2012; 12: 2446-56.
    • (2012) Am J Transplant , vol.12 , pp. 2446-2456
    • Vincenti, F.1    Tedesco Silva, H.2    Busque, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.